MAM
ASND icon

Melqart Asset Management’s Ascendis Pharma A/S ASND Stock Holding History

Melqart Asset Management’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-115,404
Closed -$16.1M – 40
2019
Q4 		$16.1M Buy
+115,404
New +$12.8M 1.35% 22

Other funds holding ASND

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Melqart Asset Management's ASND Position: Q1 2020 in Review

Melqart Asset Management sold out of Ascendis Pharma A/S (ASND) in Q1 2020, closing a stake of 115,404 shares — an estimated $16.1M sold.

Melqart Asset Management first reported a position in ASND in Q4 2019 and held it in 1 quarter. The position peaked at $16.1M in Q4 2019. 147 funds tracked by Wall St. Rank hold ASND as of Q1 2020.

  • Melqart Asset Management reported no remaining Ascendis Pharma A/S position as of Q1 2020 after selling out during the quarter.
  • Melqart Asset Management sold 115,404 Ascendis Pharma A/S shares in Q1 2020, an estimated $16.1M.
  • Melqart Asset Management first reported a position in Ascendis Pharma A/S in Q4 2019 and held it in 1 quarter.
  • Melqart Asset Management's Ascendis Pharma A/S position peaked at $16.1M in Q4 2019.
  • 147 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2020.

Based on Melqart Asset Management's 13F filing for Q1 2020, filed 15 May 2020.